Since the therapeutic efficacy of PD173074 has been investigated and proven in various cancers but also non-cancerous diseases and already entered clinical testing [17, 34–36], our findings expand our knowledge of a putative role of NCAM/FGFR in EMT program initiation and renal fibrosis and it is attractive to speculate that specific modulation of such NCAM/FGFR signaling could be equally effective in the treatment of renal disease associated with aberrant EMT program. Here, NCAM1 is linked to kidney disorder.